Stats

1. Sep9 delayed SIP firstminute CHWYopen21.85 vs23.27close=-6.1023%;13:36C21.32=-8.3799%. SPYopen764.08vs765.96=-.2454%, does not explain all company decline; not causal attribution. Prior20SIP CHWYSMA23.378/ADR.91168, LOVE16.47025/.655065, SPY768.6995/4.46606. 2.09:50IEXminuteC21.59 distinct from13:52:36IEXbid21.67ask21.70, exactcurrentSIPNBBO403. LOVEIEXtrade staleSep8 andwidequote cannot size exits. 3. LOVEpaper frozen1677 Sep9open15.87→stop15.214935,target16.8525975,timeexit19:45UTC; observe15minclose thennextopen, fee/slip retained. No completed paperoutcome beforetime. Rebound is counterexample to assumingnegativegap meansfurtherloss; no tested drift rule. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=CHWY,LOVE,SPY&timeframe=1Min&feed=sip&adjustment=all . Observations18520–23 preserve fullcalculation/input timestamps. These are bars, notfills; remainzero.

1. Direct issuer SEC Sep9 Q2 endedAug2 reports organic growth5.7%,total7.3%,EBITDA6.8%; OCF137.4m versus133.9,FCF89.5 versus105.9. 2. Python cash bridge +3.5m OCF minus19.9m incrementalcapex gives -16.4mFCF (-15.4863%). Therefore FCF deterioration does not prove demand or collections deteriorated; higher investment is the immediate explanation. 3. Syndicated issuer presentation PUBT gives FY13.46–13.57bn and6.7–6.8%margin,Q3sales3.323–3.358bn and6.6–6.7%margin. Exact original/priorguide/call unavailable, so magnitude of raise unverified; do not claim organic acceleration from acquisitions. Strongest counterargument investment delivers high future returns and rising operatingcashsupports it; next evidence needs clinic/pharmacy economics and retainedcash. Conclusion watch fundamentals, no price payoff or valuation established. One company origin across SEC and syndication. Sources https://www.sec.gov/Archives/edgar/data/1766502/000162828026061011/chwyq22026exhibit991.htm ; https://www.marketscreener.com/news/chewy-second-quarter-2026-earnings-presentation-ce785bd9dc8df026 ; primary IR blocked https://investor.chewy.com/financials/quarterly-results/default.aspx .

Startstatecrypto235.86cash/system850.99,goalrepeatablenetprofit,bindingconstraintvalidatedpositiveentrypayoff. Numberedpremises:1 1726 frozen daily/hourly/15min families rejected, allquarterKelly0; no new backtest needed to preserve rejection.2 1727 fresh primaryflow/custody review finds no newly dated spot demand or verified authorized recovery; missing disclosures/explorer access remain unknown.3 1728 fresh9/10quotes and~.52–.60%majors fee/spread hurdles do not create edge, topask belowcap.4 QuerytradesonlyN1operatorliquidation, no holdings/queuedorders to exit/adjust. Conclusion No proposals. Validity: absence of required evidence implies0authorizedsize; soundnesslimitedbyhistoricalomissions,assumedfees/slippage,publication/destinationunknown. Strongestcounterargument an unseen newflow or rally could create opportunity; accept opportunitycost without bearishforecast. Prior expectedcash stance unchanged by349.01shortfall; more independent positivecoststressed30+prospectivesamples plus executiongates could change it, a quote/newsrepeat cannot. Sources https://runway.adityaperswal.workers.dev/data/crypto-bars ; https://runway.adityaperswal.workers.dev/data/crypto-snapshots ; https://data.sec.gov/submissions/CIK0001326380.json ; https://www.circle.com/transparency ; https://blockstream.info/liquid/api/blocks . Monitor129resolved,138next16:30,45macroretained. Jobs139/140/141requested through16:31 afterlocaltests; no savednewoutput at13:54, coveragegapexplicit,14/25preserved. Technical/execution/psyche lessons531–533 recorded. Elapsed~5minutes within27plan and45hard; no orders.

Numbered premises:1. Supply ledger allcash278.67, account850.99, no open/pending/closing lots; only2closedoperatorliquidations https://runway.adityaperswal.workers.dev .2. Fresh fundamental1723/consequences1724 and observations18500–11 include original URLs: no new accepted cash verified in bounded FRO/ASPI/SEI/OESX review.3. Statistical1725 preserves frozenFRO41meanCI[-.874362,1.958541]% and rawquarterKelly2.4267%,approved0; ASPI-47.66%N24,SEI-48.92%N6,OESX-31.81%N4 remain rejected from prior1702/monitor128. Source https://runway.adityaperswal.workers.dev/data/stock-bars .4. Technical1702/indicators1631 and simulation1630 reused as saved research, not fresh indicators/path runs; positive trigger does not repair uncertainty. Conclusion no PROPOSE/EXIT/ADJUST/FUND; holdcash. Valid under quantified-edge mandate; soundness limited by issuer bias, missing Q&A/fixtures and15minute fill uncertainties. Strongest counterexample truepositiveFROexpectancy is plausible, requiring independentprospectivecosted evidence rather than reoptimization. No candidate qualifies for quote/stop/target/lot construction. Monitor128 completed; initial successor request422at20monitorcap, retried afterresolution and139accepted16:30UTC. Fiveexistingjobs retained including116hourly; no newjob needed. Preserve78macro,11FROdividend,133ASPIquarterend. Finishphase13:53 (~2.3min elapsed), completed within42minute allowance/hard45 with entire5minfinish reserve available; no thread overran. Lessons528–530 saved.

Premises:1 No approved daily/hourly/15minute entry rule in1726.2 Same completed Sep8 daily data as1700: RSI2 BTC16.527 ETH40.992 SOL36.248 above frozen10; no intraday substitution or new backtest.3 Sep9 13:52 primary BTC79266.7/79287.555 ETH2509.66/2510.19 SOL104/104.1 age.5/3.1/4.1s; credited-asset25bp each-side assumed fees plus bidask recovery hurdles .5283/.5231/.5985%. Topask dollars79.84/83.74/99.37 below212.7475 cap, not full depth/fill guarantee.4 No position or queuedorder to review R, target progress or horizon. Conclusion no new entry/exits; no fabricated stop/target. Prior WilderATR14 from1700 2257.4264/89.54047/5.056536 only rangecontext. Counterargument limit savings could help but independent fills/adverse-selection history absent and entry remains rejected. https://runway.adityaperswal.workers.dev/data/crypto-snapshots ; https://runway.adityaperswal.workers.dev/data/crypto-bars ; https://docs.alpaca.markets/us/docs/crypto-fees .

Premises:1 Sep9 13:52 SEC index latest10QJune11, latestearnings8KSep8; updated quarterly BTCquantity/counterparty/spot timing unavailable.2 Issuer IBIT/ETHA CSVs stillSep4, quantities785635.3173BTC/3527867.3679ETH: stocks not current purchases.3 Circle Sep7 seven-day8.8bn issued-7.86bn redeemed=.94bn,134.286m/day average; no new publication. USDCweb dateUNPARSED and LlamaSep9 different population cannot give incremental matched flow.4 Liquid tip4051232 age57.0586h; secondaryfailed; operator preparation wording hashunchanged; recipient598.50017761BTC/reserve3601.47202426 and small controlled tx do not prove authorized recovery. Conclusion retain uncertainty and cash; absence of a disclosure is not no activity or delay. Sources closest to event but issuer/operator interested and explorers incomplete. Counterargument buying/recovery could precede publication, which leaves timing unidentified. First order successful recovery could release assets, second holders may sell/hold/hedge, third price response and costs can absorb it; beneficiaries are claimants and intermediaries without known spot-buy requirement. Observations18498,18513,18514. https://data.sec.gov/submissions/CIK0001326380.json ; https://www.ishares.com/us/products/333011/ishares-bitcoin-trust-etf/latest-holdings.csv ; https://www.ishares.com/us/products/337614/ishares-ethereum-trust-etf/latest-holdings.csv ; https://www.circle.com/transparency ; https://www.usdc.com/ ; https://stablecoins.llama.fi/stablecoin/2 ; https://blockstream.info/liquid/api/blocks ; https://x.com/Blockstream .

Premises:1 Positive independently validated cash expectancy required.2 Frozen1639–1641/1698 daily/hourly/15min rules fail; arithmetic using exact wins35/82,27/61,33/70 and recorded average wins/losses still negative.3 OwnN1 forced liquidation cannot estimate setup edge or execution distribution. Conclusion allocation0. This is arithmetic verification, not new backtest, parameter change or independent data. Already-recorded costed vectorbt holdouts BTC-43.5409%,ETH-32.9637%,SOL-18.7330%; pullback family separately only1–5 OOS trades and rejected. Sampling omissions, serial dependence and cost assumptions limit inference; a future rebound is a counterexample to a bearish prediction, not to the absent validated edge. Existing simulation1652 remains sensitivity only. https://runway.adityaperswal.workers.dev/data/crypto-bars ; https://docs.alpaca.markets/us/docs/crypto-fees .

Premises:1. Query readback1697/1702 retains frozenbacktest456 2022–24training/2025–Sep4holdout, fixed next-open20-closebreakout/1ADRstop/2ADRtarget/5sessions with costs; prior CLI audited as mismatched execution proxy. Source https://runway.adityaperswal.workers.dev/data/stock-bars .2. Python arithmetic18511 reproduces17/41wins and .530247%mean,rawquarterKelly2.426669%; confidence interval[-.874362,1.958541]% remains unresolved.3. query_trades supply returned only2 closed operator-liquidation winners; no empirical average loss or planned-exit validation https://runway.adityaperswal.workers.dev .Conclusion approved size0. Positive true expectancy is possible but not established; same two wins do not add an independent sample. Reuse simulation1630/technical1702 limitations without fresh paths: daily bars and fixed-payoff Monte Carlo do not prove15-minute execution. No new backtest, parameter sweep or claimed current price. Requires independent prospective costed evidence to change gate.

Premises:1. Sep8 CENTCOM claims5 carriers destroyed, separate3 Sep5; belligerent first-party source does not quantify replacement cargo https://www.centcom.mil/MEDIA/PUBLIC-RELEASES/Article/4593050/us-destroys-5-irgc-tankers-after-iran-targets-another-american-warship/ .2. SEI growth guidance includes acquisitions https://ir.solaris-energy.com/news/2026/09-08-2026-114509510 ; prior recorded Q2 supplier-rights cash131.2m went to rights owner/supplier, not equity holders https://ir.solaris-energy.com/~/media/Files/S/Solaris-IR/reports-and-presentations/10-q-2q26.pdf .3. ASPI and Orion delivery economics remain incomplete per fresh fundamental review. First order: effective vessel/equipment supply disruption can increase quoted rates or rights prices. Second: insured owners with substitute cargo or equipment-rights sellers may capture cash while buyers finance slots and bear delays. Third: demand destruction, funding costs and new capacity can dissipate equity benefit before realization. These are conditional mechanisms, not measured current netbacks. Strongest counterargument: sustained lost capacity could generate outsized profits; resolution needs paid fixtures/accepted margins and an independently validated stock return rule. Start cash, goal repeatable net profits, binding constraint measured tradable edge.

Premises:1. Frontline archive latest Aug28 results; no new replacement-fixture receipts in inspected list https://www.frontlineplc.cy/category/press-releases/ .2. ASPI Sep8 prospective production/shipment language remains, full Q&A unavailable https://ir.aspisotopes.com/news-events/press-releases/detail/119/asp-isotopes-hosts-inaugural-capital-markets-day-and and https://ir.aspisotopes.com/news-events/capital-markets-day .3. SEI H2 midpoint282.5m vs207.5m includes acquired businesses and is adjusted EBITDA, not actual September accepted cash https://ir.solaris-energy.com/news/2026/09-08-2026-114509510 .4. OESX Sep8 second hyperscaler facility order follows June; issuer relays customer praise without exact margin/receipts https://investor.oriones.com/news-releases/news-release-details/orion-announces-additional-multimillion-dollar-data-center .Conclusion retain watch, no new cash bridge overturns previous gate. Observations18502/18506/18508–10 contain dates/provenance. Soundness limited by bounded published pages; absence of disclosure does not prove no deliveries. Counterexamples: ASPI might already have accepted product, SEI organic growth might dominate acquisition effects, and Orion might have strong margins. These require customer acceptance and cash evidence; valuation is not refreshed because no candidate passes stock payoff gate.

Start49.14fundcash,850.99equity,zeroownholdings/queuedorders perqueriedledger; goalrepeatablepre-eventgains. Bindingconstraint independent net actual-windowedge, not349.01monthlyshortfall. Premise1 readnotes/lessons513–515 andfrozen38/1677/1688/1682with1685Kellycorrection:CHWYholdout-1.72%N6;LOVErequiredexits-.3685%N10/stress-2.3414%,allmeanCIsinclude0. Premise2 now8issuercompletedreleases1710–17 give mixedcashandimprovingoperations; favorableBRZEcashandGMEguidance are strongestcounterarguments, butposteventstrategyunvalidatedandpre-eventwindowelapsed. Premise3 prospectiveCHWYpaper-2.687668%N1 (18490/1718) doesnot rehabilitaterule. Premise4 technical1719/reusedsimulation1720 cannot manufacturepositiveentryedge. Conclusion allocations0andnoproposals: no order/stop/targetneedsmaintenance; no newbacktestneeded torepeatfrozenrejections. Validity: absentrequiredvalidatededge, mandatedsize0follows. Soundnesslimitedbysmallselectedsamples, feed/timezoneinconsistency, firstnewsminuteunknown, nofullcurrentbidask andunreadcalls; nonepermitspositiveallocation. Evidencewouldmoveaction: independentlypreregisteredcostedwindow/venuecadenceholdoutwithcrediblepositiveexpectancyplusfreshquotesanddocumentedpre-eventexit. QuarterKellycapitalformula(p/L-(1-p)/W)/4,thenuncertainty/fund49.14/position212.7475/risk8.5099caps; currentunknownorfailededge->0. Review12/15/17/18/32/126resolved;135CHWY13:50,136ASO/KFY16:30,137LOVEtomorrowarmed;futureFDAmonitorspreserved. Collector118truncated2000chars replacedafter1803bytecomplete11paneltest by138, actualfirstsandboxpending;132actualfullfooterverified. Gaps: exactCHWYguide,ASOrefund10Q,KFYcash/AMS,GME37.7marknetting,organicBRZE/SAIL/CNMbridges; AVO/PPIHoverflowfollowupsnotcompletedthisboundedtradingreview. Full URLs in1710–21 andobservations. RawfundamentalprimarydatesSep8/9; no guessingcalendar. Sources: https://www.sec.gov/Archives/edgar/data/1766502/000162828026061018/chwy-20260802.htm ; https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=LOVE,SPY&timeframe=15Min&feed=sip&adjustment=all .

Premises primaryfundamentals1710–17 showdemandgrowthcoexistingwith cash/financingconstraints. Firstorder: Chewy/SailPoint acquisitions andsoftware/capex consume cash despite customer/ARRgrowth; Academyper-shareprofits benefit fromlowerdenominator; Caseyfuelmargincapturesmoregrossprofitthaninsideincrement. Secondorder (inference): suppliers, acquiredowners, employeesreceivingequity andrepurchasingstockholders can capturecash ahead ofremainingowners; CNMpayablesfinanceinventorywhilecustomersdefercash, KFYAMSguidanceaddsacquiredscale. Thirdorder (conditional): sustained investmentcashreturnswouldimproverecurringper-sharevalue; slowcollections/dilution/costnormalizationwouldshiftneedtoward externalfundingandreducepricepayoff. Strongestcounterargument theseinvestmentsmayproducehighfutureROIC; currentlymeasuredquartercashdoesnotsettleit. No competitortradeorFUNDproposalbecauseindependentstockpayoffunknown. Source-origin eightissuers, releasesandtheirSECcopiesareoneoriginapiece: https://www.sec.gov/Archives/edgar/data/1766502/000162828026061018/chwy-20260802.htm ; https://www.sec.gov/Archives/edgar/data/1817358/000181735826000146/exhibit991pressreleaseq220.htm ; https://investor.sailpoint.com/static-files/b83fe64e-3bb0-41aa-aa9a-acf0940242e4 ; https://www.sec.gov/Archives/edgar/data/1856525/000185652526000091/cnmq22026earningspressrele.htm ; https://ir.kornferry.com/news-events/press-releases/detail/733/korn-ferry-announces-first-quarter-fiscal-2027-results-of-operations ; https://www.sec.gov/Archives/edgar/data/1676238/000167623826000039/a20260731-brazeincxq227ear.htm ; https://news.gamestop.com/news-releases/news-details/2026/GameStop-Discloses-Second-Quarter-2026-Results/default.aspx ; https://investor.caseys.com/news-releases/news-release-details/caseys-announces-first-quarter-results-3

No new simulation or invented live forecast. Read1682:NumPyseed2026090908,50000resamplesof10empiricaltime-onlyreturns over10hypotheticalevents; 25%capitaldeploymentmeanterminal51.17792from49.14,5/50/95quantiles47.38995/50.79397/56.33595,lossprobability25.418%. Fullcapitalmean57.63877/loss26.782%; constantcash49.14. 1. These eventsarenot10days oravailablemonth-endopportunities. 2. SelectedN10time-onlydistribution dominatedbyonebroadmarketday; mandatoryexitcoststressnegative, pathsaddnopopulationinformation. 3. Analysis1685 andlesson514 supersede1682paragraph3cash-Kellyinterpretation; use(p/L-(1-p)/W)/4 forcapital. Conclusion favorableconditionalmeanisanexplicitcounterargumenttocashbutunsupportedforactualwindow, adoptedfraction0. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=LOVE,SPY&timeframe=15Min&feed=sip&adjustment=all ; prior1682/1685. No need togenerateanother50000paths fromsameunstableinput.

1. Sep8IEXCHWY23.27belowSMA20 23.3815;LOVE16.12below16.4585;SPY766.06below768.6585. ADR20 respectively.874/.42425/4.407. Completed prior-session context only, no freshbidask. 2. LOVEpreviousSIPclose16.07/ADR.655065 differs from IEX: cannotreplace feed-specific range with smallerstop andclaim1677validation. 3. Fixed mandatoryexitLOVE1677N10 -.3685%base/-2.3414%stress,meanCIcrosseszero; CLI1688N56 -17.85%no-feeunsplit diagnostic alsofailed. No newbacktest rerun because no changedeligibleedge; currenttechnicalstatescannotrepairnegativecoststress oruncertainty. Conclusion noentry/stop/targetproposal. Strongestcounterexample dipbelowSMAcouldprecederebound; independentlytestthatnewrulebeforetrust. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=CHWY,LOVE,SPY&timeframe=1Day&feed=iex&adjustment=all ; SIPtest https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=LOVE,SPY&timeframe=15Min&feed=sip&adjustment=all .

1. Queried Catalyst ledger contains3closedlosses,0open/pending/closing,2operatorliquidations censor intendedhorizons. Pythonreturns MIRM-.439321%,IONS-2.842420%,RARE-45.860062%;meanloss16.380601%,winrate0/3,avgwinnerundefined. No positive edge estimate from ledger; sample too small toprove allfutureedgesnegative. RAREexit13.98976 vsstop24 =41.7093%worse, gapnotboundedbylogicalstop. 2. Separate frozenCHWY38 prospective N1 paper: Aug25IEXopen24.47 toSep8open23.86,5bpfee/slip eachside net-2.687668%; negative newobservation, not appendedtohistoricalholdout toretuneparameters. OriginalhistoricalN6p50%,W4.523391%,L4.828695%,mean-.152652%,return-1.719988%,DD14.258614% retained. 3. Costs andcorrectedcapitalKelly(p/L-(1-p)/W)/4 implynonpositiveCHWYcapital; adopted0. Sources runway:query_trades?fund=catalyst ; https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=CHWY,LOVE,SPY&timeframe=1Day&feed=iex&adjustment=all . No fabricatedavgwinner or pricededge.

1. Q1EBITDA+17.1%,insidecomps+3.2%,margin42.2%improve. 2. Fuelmargin47.8cvs41.0c,same-storegallons-.3%; fuelaccounts62.33%incrementalcombinedinside+fuelgrossprofit,so earningsgrowthnotjustcustomervolume. 3. OCF384.072m+3.13%,capex194.395m vs110.046; cashaftercapex189.677m falls27.71%before43.904macquisitions; FCFproxydefinedexplicitly. FYEBITDAgrowth8–10%unchanged despitequarterstrength. Conclusion operationallypositivebutfuelmargins/capexpayoutwindowcanlimitnear-termcash; no independentlyvalidatedpriceedge. Strongestcounterargument investmentscreatefuturestorecashandfuelmarginmaybe durable; requirenewstorepaybackandnetactualwindowtest. No whole-shareaffordabilityclaimfromstaleprice. Primary https://investor.caseys.com/news-releases/news-release-details/caseys-announces-first-quarter-results-3

Sep9 premarket review; issuer-source facts separated from derived arithmetic and inference. 1. Actualsales790.2m,operatingincome160.2m,net298.7m allwithinAug31prelimranges; largeYoYoperatinggainwasalreadydisclosed. 2. >650mEBITDAguide versus>600m isnewexpectation (+8.33%floor), collectibles356.3m/45.1%mixsupportsoperatingshift. 3. Q2FCF60.7m falls46.43%vsH1FCF+29.94%: differentperiodsreconcilecashnarratives. Investmentgains/digitalassetmarksarenotoperatingincomeorverifiedspotflows; releasecashflowderivative203.6+equity72.1 differsfromprelim~238net,37.7gapneedsfullfilingdefinitions. Conclusion favorableguidance butcurrentpre-eventwindowwascontaminatedAug31; no run-upreentry. Strongestcounterargument collectiblesmixandsavingssupportrecurringprofit; requirecashconversionandindependenttestedstockedge. Do not countpressreleasecopiesasindependentconfirmation. Primary: https://news.gamestop.com/news-releases/news-details/2026/GameStop-Discloses-Second-Quarter-2026-Results/default.aspx

Sep9 premarket review; issuer-source facts separated from derived arithmetic and inference. 1. Revenue227.2m exceeds219.5–220.5guide; subscriptiongrowth20.90% trails total26.2%, services+136.14% changesmix. Organicdefinitionprovided butnonnumericacquisitionbridgeremainsgap. 2. GAAPGM66.8vs67.7%,NRR110vs108%; GAAPoploss18.1m improves,adjustedop22m. 3. FCF21.744m vs3.533improves substantially aftercapex/software; SBC35.661m stilllarger, FCFlessSBC-13.917m economicproxy. Conclusion bettercashandretention are crediblefutureevidence, not validatedpost-earningsdrift. Counterexample investedservices mayhelp futureSaaSretentionratherthanlowqualitysales; requireorganicmix/costandfuturecohortanalysis. FYrevenue910–913m/adjustedEPS.64–.65; nointrinsicvaluationortradetargetestablished. Primary: https://www.sec.gov/Archives/edgar/data/1676238/000167623826000039/a20260731-brazeincxq227ear.htm

Sep9 premarket review; issuer-source facts separated from derived arithmetic and inference. 1. Q1feerevenue756.5m+7%actual/constantcurrency,bookings832.3m andremaining1915mimprove. 2. EBITDAmargin17%flat, GAAPmargin9.1vs9.4%; growthnotmarginexpansion. 3. Q2guide860–878mincludesAMSSept/Oct afterSep1close, so jumpcannotbecalledorganic. Releasehasno cashflowstatement andsubmissionfeednoQ110Qyet: cashaftercapex/SBCunknown, notzero. Conclusion prospectivebusinessimprovementbutno executablepre-eventwindow/independentposteventedge. Counterargument crosssellingAMSraisesfuturereturns; requires financedpurchaseprice, incrementalearningsandcashbridge. NoonETcallpending; successorwillcheckfullresults/filing. No purchase. Primary: https://ir.kornferry.com/news-events/press-releases/detail/733/korn-ferry-announces-first-quarter-fiscal-2027-results-of-operations

Sep9 premarket review; issuer-source facts separated from derived arithmetic and inference. 1. Q2sales2145m+2.5%,EBITDA274m+3%,GM26.7vs26.8%; municipal/fire/datacenterstrength ismanagementattribution, exactorganicgrowthunreported. 2. H1sales+1.3%primarilyacquisitions, EBITDA500m, OCF144m:28.8%conversion versusFYguide60–70%. 3. Reaffirmed950–980mEBITDAimpliesFYOCF570–686m andH2need426–542m; this is guide arithmetic, not forecast. H1FCFproxy112m beforeTRA42m andbuybacks257m; payablecashsource301vs196m helpscash. Conclusion underlyinggrowthpositivebutcashseasonality/unwindremainsbinding; no run-upentry afternews. Strongestcounterargument seasonallystrongH2collections canachieveguide; would need historicalseasonaldistribution andactualcollections beforerejectingguide. No new valuation or validatedeventedge. Primary: https://www.sec.gov/Archives/edgar/data/1856525/000185652526000091/cnmq22026earningspressrele.htm

Sep9 premarket review; issuer-source facts separated from derived arithmetic and inference. 1. ARR1231m+25%,SaaS847m+36%,RPO1.9bn+30% support contractgrowth; Entroacquisition contribution not separated. 2. Q2revenue308.813m+17%,GAAPGM66.5vs67.3%,adjustedopmargin20.3vs20.4%; GAAPoplosswidens58.958m. 3. FCF37.409m falls18.60%, SBC68.321m=22.12%revenue; FCFlessSBC-30.912m sensitivity is economicdilutionproxy, notactualcashburn. H1improvement heavilyconfounded by priorIPO/interest/advisorycash. Conclusion AI/ARRnot demonstrated acceleration in per-share cash. Strongestcounterargument subscriptionmix improves futureconversion andSaaSnetnewARR dominant; monitor rather thaninfer stockpayoff. FYrevenue1265–1275m, adjustedop239–244m; acquisition-adjustedreturn unverified. Allocation0. Primary: https://investor.sailpoint.com/static-files/b83fe64e-3bb0-41aa-aa9a-acf0940242e4

Sep9 premarket review; issuer-source facts separated from derived arithmetic and inference. 1. Q2sales+3%,comps-.4%,327storesvs306: reportedgrowthdoesnot prove same-store recovery; mid-single-digit newstorecomps are not cohortROIC. 2. EPSguide+$.10 while netincomeunchanged andsharecount66→64.5m; mechanical capitalstructure contribution matters. 3. Marginguide+100bp andFCFguide+50m positive, but Q2OCFincludes tariffrefunds andH172.224m remittance sits infinancing. H1adjustedFCF237.558 lessremittance165.334m is cashclassification sensitivity, not recurring normalization; exactQ2bridgepending10Q. 4.Inventory+4.4% butperstore dollars-2.3/units-5.6% reconciles footprint growth. Conclusion cash evidence improves but sourceandper-sharebridgesprevent treating headlineEPSasorganic acceleration. Counterexample customertraffic andnewbrands could improve futurecash; require cohortpayback andcostedindependentstockrule. No post-release purchase. Primary: https://www.sec.gov/Archives/edgar/data/1817358/000181735826000146/exhibit991pressreleaseq220.htm

Sep9 premarket review; issuer-source facts separated from derived arithmetic and inference. 1. Q2 organic sales +5.7% trails reported7.3%; customers+3.8% and Autoship+9.3% support demand. 2. EBITDAmargin6.8% improves YoY5.9%, but Q1 derived7.54% was higher; Q1baseline73 sales3357.2,GM30.1%,customers21.497,Autoship84.4%,FCF70.8. Q2GM30.4% includes~30bp tariff/rebate benefits and prior also had nonrecurringvendorbenefits. 3. Q2FCF89.5m improves sequentially but falls15.49%YoY ascapex+71.07%; H1FCF+3.7% despite larger adjustedprofitgrowth. Acquisitioncash552.8m andrepurchases400m need financing bridge. Conclusion mixed operatingimprovement, no newpre-evententry afterrelease. Strongest counterargument recurringAutoship/ads could accelerate futuremargin; that raisesresearchpriority, not odds from failedtest38. Guidance raise asserted byCEO inSECexhibit but exact revisedranges/call details unverified; retain next-run check. Dollar values USDm; no valuation target justified. Primary: https://www.sec.gov/Archives/edgar/data/1766502/000162828026061018/chwy-20260802.htm

Start187.22USDQuantcash,850.99account;goalrepeatablepositivecashreturns;bindingconstraintvalidatednetedge. P1 Re-readoriginalbacktest1642:2016–20training,2021–25holdout,nextopenIBS<=.2with1ADRstop/1.5ADRtargetorclose,1bpfee+5bpslippageeachside. EEM252holdoutreturn-21.6318%,DD25.2062%,p45.6349%,cashavgwin.490802%/loss.585548%,Kelly0;16bpssidestress-52.6571%. All8primaryholdouts/all72stresscellslose. No fresh optimization orborrowedpositive2026extension; recorded backtest re-used,NOT rerun. P2 Clinicalsource1703findsTYRAprimary8/14differentheadline8/8;IRDfullslidesnonprespecifiedloci/conditionalfunding;INBXunchanged. P3 Technical1707recordsTYRA-34.53%/IRD+12.56%delayedpremarket;neitherdirectionestablishesindependentstockdrift,quotesstale/wideand15minexitmodelabsent. P4 Owntrade1705N3censoredoperatorliquidationsKelly0;simulation1706illustrativeonly. ConclusionnoPROPOSE/EXIT/ADJUST/FUND. Deductionvalidundermandate;source/providerqualityconditional,notclaimallquantstrategiesfail. Counterargumentcheapexecutionorclinicalbreakthroughcouldgenerateedge,butcannotrepairfailedtestorunmeasuredtradepayoffwithoutnewindependentvalidation. Resolve47/48/121;successor134at13:50coversclinicalfullsources/regularopen,job137bounded15m7runsuntil14:15hardcutoff. Preserve15/84/85/131and60/42/127. Ledgerzeroallstatusesreverified12:39. Finalrecordphasebegan12:37,overall~9minatdecision;under35plan/45hard. GapsTYRAfullslides/webcastnotretrieved(exacteventURL200butnolinks),independentFDAminutes,unconditionalIRDfunding,liveSIPentitlement403,untouchedclinicalpriceholdout. Allgapsretainzeroallocation. Sources https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT06995677 ; https://ir.opusgtx.com/presentations ; https://inhibrx.com/hexagon-slides/ . Lessons522–524; observations18376–18401/18449–51; analyses1703/1705–1708.

Startclinicalproof-of-concept,goalrepeatablecashstockedge,bindingconstraintindependentcostedstockpayoff. Chain1:TYRAoralactivitymayimprovetreatmentacceptance;thenadjuvantcontrolledtrialmustdemonstraterecurrencebenefitanddurability;thenapproval/adoption/reimbursementmustproducecashabovecontinueddevelopment/dilution. Counterexamplescatheteravoidancedoesnotproveefficacy,activityinselectedmarkerlesionsdoesnotmeasureadjuvantrecurrence. Chain2:IRDlocalizedvisiongainsmayjustifyearlier-stageenrollment;thenprespecifiedloci+PROrandomizedpivotaltestmustreplicatewithcommercialmanufacturing;thenfundingconditionsandpayeraccessdetermineequityvalue. Counterexamplenonprespecifiedlociand5differentpatientsinflatesapparentconsistency;cash2029projectionincludespotentialcredit. Patients/sponsors/investorsmaybenefit;furtherfundraisingalsobenefitscashrunwaybutdilutesexistingowners. Bothvalidmechanismchainsarehypotheses,numericalstockprobabilityunidentified. Strongbullcasefuturetrialsuccesscouldrevaluefirms; current+12.56%IRDand-34.53%TYRAonlyshowoppositerepricing,notcausaldemonstrationorremainingalpha. Sources https://tyrabio.investorroom.com/2026-09-09-Tyra-Biosciences-Reports-Initial-Phase-2-SURF302-Results-Supporting-the-First-Potential-Oral-Innovation-in-LG-IR-NMIBC-with-Dabogratinib ; https://d1io3yog0oux5.cloudfront.net/_2f637757c76afd53c5f9cfd976bdd13e/opus/db/601/7992/pdf/BEST1+Cohort+1+Data+Presentation+-+Final+-+9.09.26.pdf ; https://ir.opusgtx.com/press-releases/detail/540/opus-genetics-announces-financial-results-for-second-quarter-2026-and-provides-corporate-update .